“Development and Doe-Based Optimization of a Microencapsulated Crisaborole Drug Delivery System”

The formulation of microcapsule containing crisaborole by Design of experiment. Microencapsulation, a widely adopted technique, enables the controlled release of active pharmaceutical ingredients (APIs) by encapsulating them in a protective polymer matrix. Microcapsules spherical shape and smooth surface morphology were demonstrated by a scanning electron micrograph with a magnification of 150.59 KX. The entrapment efficacy of produced optimized Microcapsules was found to have a high drug entrapment efficiency of 93.78%. The melting point (131°C) fell within the reference range, confirming purity and the absence of significant impurities. The pH of the drug sample (5.3) lies within the acceptable dermal application range, supporting its compatibility with skin physiology and reducing the risk of irritation. The solubility study showed that Crisaborole is highly soluble in methanol, moderately soluble in ethanol and acetone, but practically insoluble in water, indicating the need for specialized delivery systems. The UV spectroscopic analysis determined the λ max at 250 nm, and a linear calibration curve was established between 2–12 μg/mL concentrations. The high % RSD value (49.746%) suggests the need for improved analytical precision in future studies. FTIR analysis confirmed the structural integrity and compatibility of the drug in formulations. Overall, the results validate Crisaborole’s potential as a candidate for stable, effective topical formulations and as a drug encapsulated in polymeric Microcapsules to improve its solubility and therapeutic efficacy. The research concludes that the application of DOE in Microcapsules formulation allows for a systematic and efficient approach to developin